Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press124010.17650/1726-9776-2006-2-1-17-25DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак почкиModern Approaches to the Treatment of Renal Cell CarcinomaСовременные подходы к лечению почечно-клеточного ракаKirkaliZiyaКиркалиЗия
Turkey

Izmir 35340

Erdem CandaA.Эрдем КандаA.
Turkey

Izmir 35340

Dokuz Eylul University School of Medicine, Department of UrologyDokuz Eylul University School of Medicine Department of Urology300320062117252102202021022020https://oncourology.abvpress.ru/oncur/article/view/1240

Surgery is the only effective method for the treatment of localized renal cell carcinoma (RCC). Today nephron sparing surgery (NSS) cures the majority of patients with early stage disease. Open radical nephrectomy (RN) is performed mainly in patients with large tumors and in cases complicated by the tumor thrombus extension into the vena cava. Laparoscopy is now more and more often used for RCC treatment. Laparoscopic RN (LRN) is now recommended for the treatment of early stage RCC, when NSS cannot be used. LRN seems to provide longterm cancer control comparable to open RN. RCC is now often diagnosed when the tumors are still small and can be often cured by NSS providing excellent local cancer control. Tumor size, location, multiple foci, surgical margin, and pathological variants are significant for cancer outcome in selective NSS. Laparoscopic partial nephrectomy (LPN) is now gaining popularity as an effective minimally invasive treatment in patients with relatively small and peripheral renal tumors. Recently minimally invasive ablative techniques were introduced for the treatment of RCC. These methods involve little complications if used for the treatment of small renal tumors. The currently used best therapy for metastatic RCC is inadequate and surgery is an important component of combined treatment including immunochemotherapy. Combinations of interferon-alpha, interleukin-2, and 5-fluorouracyl are now used for the treatment of metastatic RCC. Nephrectomy can be recommended for patients with good performance status before immunotherapy. Modern research is focused on identification of novel agents and treatment modalities with better antitumor activity.

.

1. Jacqmin D., van Poppel H., Kirkali Z., Mickisch G. Renal cancer // Eur. Urol. — 2001;39:361—369.Jacqmin D., van Poppel H., Kirkali Z., Mickisch G. Renal cancer // Eur. Urol. — 2001;39:361—369.2. Kirkali Z., Yorukoglu K. Premalignant lesions in the kidney // Scientific World J. — 2001;1:855—867.Kirkali Z., Yorukoglu K. Premalignant lesions in the kidney // Scientific World J. — 2001;1:855—867.3. Pehlivan S., Koyuncuoglu M., Pehlivan M. et al. Premalignant lesions of the kidney share the same genetics changes as conventional renal cell carcinoma // World J. Urol. — 2004;22(2):120—123.Pehlivan S., Koyuncuoglu M., Pehlivan M. et al. Premalignant lesions of the kidney share the same genetics changes as conventional renal cell carcinoma // World J. Urol. — 2004;22(2):120—123.4. Kirkali Z., Lekili M. Renal cell carcinoma: new prognostic factors? // Curr. Opin. Urol. — 2003;13(6):433—438.Kirkali Z., Lekili M. Renal cell carcinoma: new prognostic factors? // Curr. Opin. Urol. — 2003;13(6):433—438.5. Kirkali Z. Limits of cure by surgery in renal cell carcinoma / In Kurth K.H., Mickisch G.H., Schroeder F.H. eds // Renal, Bladder and Prostate Cancer, an Update. Bath: Parthenon Publishing Group. — 1999:15—22.Kirkali Z. Limits of cure by surgery in renal cell carcinoma / In Kurth K.H., Mickisch G.H., Schroeder F.H. eds // Renal, Bladder and Prostate Cancer, an Update. Bath: Parthenon Publishing Group. — 1999:15—22.6. Lam J.S., Shvarts O., Pantuck A.J. Changing concepts in the surgical management of renal cell carcinoma // Eur. Urol. — 2004;45(6):692—705.Lam J.S., Shvarts O., Pantuck A.J. Changing concepts in the surgical management of renal cell carcinoma // Eur. Urol. — 2004;45(6):692—705.7. Tsui K.H., Shvarts O., Barbaric Z. et al. Is adrenalectomy a necessary component of radical nephrectomy? UCLA experience with 511 radical nephrectomies // J. Urol. — 2000;163:437—441.Tsui K.H., Shvarts O., Barbaric Z. et al. Is adrenalectomy a necessary component of radical nephrectomy? UCLA experience with 511 radical nephrectomies // J. Urol. — 2000;163:437—441.8. Blom J.H., van Poppel H., Marechal J.M. et al. Radical nephrectomy with and without lymph node dissection: Preliminary results of the EORTC Randomized Phase III Protocol 30881 // Eur. Urol. — 1999;36:570—575.Blom J.H., van Poppel H., Marechal J.M. et al. Radical nephrectomy with and without lymph node dissection: Preliminary results of the EORTC Randomized Phase III Protocol 30881 // Eur. Urol. — 1999;36:570—575.9. Minervini A., Lilas L., Morelli G. et al. Regional lymph node dissection in the treatment of renal cell carcinoma: is it useful in patients with no suspected adenopathy before or during surgery? // BJU Int. — 2001;88(3):169—172.Minervini A., Lilas L., Morelli G. et al. Regional lymph node dissection in the treatment of renal cell carcinoma: is it useful in patients with no suspected adenopathy before or during surgery? // BJU Int. — 2001;88(3):169—172.10. Fenn N.J., Gill I.S. The expanding indications for laparoscopic radical nephrectomy // BJU Int. — 2004;94(6):761—765.Fenn N.J., Gill I.S. The expanding indications for laparoscopic radical nephrectomy // BJU Int. — 2004;94(6):761—765.11. Portis A.J., Yan Y., Landman J. et al. Long term follow up after laparoscopic radical nephrectomy // J. Urol. — 2002;167:1257—1262.Portis A.J., Yan Y., Landman J. et al. Long term follow up after laparoscopic radical nephrectomy // J. Urol. — 2002;167:1257—1262.12. Desai M.M., Strzempkowski B., Matin S.F. et al. Prospective randomized comparison of transperitoneal versus retroperitoneal laparoscopic radical nephrectomy // J. Urol. — 2005;173(1):38—41.Desai M.M., Strzempkowski B., Matin S.F. et al. Prospective randomized comparison of transperitoneal versus retroperitoneal laparoscopic radical nephrectomy // J. Urol. — 2005;173(1):38—41.13. Shuford M.D., McDougall E.M., Chang S.S. et al. Complications of contemporary radical nephrectomy: compari son of open vs. laparoscopic approach // Urol. Oncol. — 2004;22(2):121—126.Shuford M.D., McDougall E.M., Chang S.S. et al. Complications of contemporary radical nephrectomy: compari son of open vs. laparoscopic approach // Urol. Oncol. — 2004;22(2):121—126.14. Van Poppel H., Baert L.V. Nephron sparing surgery / In Petrovich Z., Baert L., Brady L.W. eds, Carcinoma of the Kidney and Testis, Rare Urological Malignancies. Innovations in Management. — Berlin, Heidelberg: Springer—Verlag. — 1999:79—93.Van Poppel H., Baert L.V. Nephron sparing surgery / In Petrovich Z., Baert L., Brady L.W. eds, Carcinoma of the Kidney and Testis, Rare Urological Malignancies. Innovations in Management. — Berlin, Heidelberg: Springer—Verlag. — 1999:79—93.15. Nieder A.M., Taneja S.S. The role of partial nephrectomy for renal cell carcinoma in contemporary practice // Urol. Clin. North. Am. — 2003;30(3):529—542.Nieder A.M., Taneja S.S. The role of partial nephrectomy for renal cell carcinoma in contemporary practice // Urol. Clin. North. Am. — 2003;30(3):529—542.16. Hafez K.S., Fergany A.F., Novick A.C. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging // J. Urol. — 1999;162(6):1930—1933.Hafez K.S., Fergany A.F., Novick A.C. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging // J. Urol. — 1999;162(6):1930—1933.17. Lerner S.E., Hawkins C.A., Blute M.L. et al. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery // J. Urol. — 1996;155(6):1868—1873.Lerner S.E., Hawkins C.A., Blute M.L. et al. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery // J. Urol. — 1996;155(6):1868—1873.18. Fergany A.F., Hafez K.S., Novick A.C. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup // J. Urol. — 2000;163(2):442—445.Fergany A.F., Hafez K.S., Novick A.C. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup // J. Urol. — 2000;163(2):442—445.19. Lee C.T., Katz J., Shi W. et al. Surgical management of renal tumors 4 cm. or less in a contemporary cohort // J. Urol. — 2000;163(3):730—736.Lee C.T., Katz J., Shi W. et al. Surgical management of renal tumors 4 cm. or less in a contemporary cohort // J. Urol. — 2000;163(3):730—736.20. Belldegrun A., Tsui K.H., deKernion J.B., Smith R.B. Efficacy of nephron-sparing surgery for renal cell carcinoma: analysis based on the new 1997 tumor-nodemetastasis staging system // J. Clin. Oncol. — 1999;17(9):2868—2875.Belldegrun A., Tsui K.H., deKernion J.B., Smith R.B. Efficacy of nephron-sparing surgery for renal cell carcinoma: analysis based on the new 1997 tumor-nodemetastasis staging system // J. Clin. Oncol. — 1999;17(9):2868—2875.21. Thrasher J.B., Robertson J.E., Paulson D.F. Expanding indications for conservative renal surgery in renal cell carcinoma // Urology. — 1994;43(2):160—168.Thrasher J.B., Robertson J.E., Paulson D.F. Expanding indications for conservative renal surgery in renal cell carcinoma // Urology. — 1994;43(2):160—168.22. Vermooten V. Indications for conservative surgery in certain renal tumors: a study based on the growth pattern of the cell carcinoma // J. Urol. — 1950;64(2):200—208.Vermooten V. Indications for conservative surgery in certain renal tumors: a study based on the growth pattern of the cell carcinoma // J. Urol. — 1950;64(2):200—208.23. Hafez K.S., Novick A.C., Butler B.P. Management of small solitary unilateral renal cell carcinomas: impact of central versus peripheral tumor location // J. Urol. — 1998;159(4):1156—1160.Hafez K.S., Novick A.C., Butler B.P. Management of small solitary unilateral renal cell carcinomas: impact of central versus peripheral tumor location // J. Urol. — 1998;159(4):1156—1160.24. Blackley S.K., Ladaga L., Woolfitt R.A., Schellhammer P.F. Ex situ study of the effectiveness of enucleation in patients with renal cell carcinoma // J. Urol. — 1988;140(1):6—10.Blackley S.K., Ladaga L., Woolfitt R.A., Schellhammer P.F. Ex situ study of the effectiveness of enucleation in patients with renal cell carcinoma // J. Urol. — 1988;140(1):6—10.25. Robson C.J. Radical nephrectomy for renal cell carcinoma // J. Urol. — 1963;89:37—42.Robson C.J. Radical nephrectomy for renal cell carcinoma // J. Urol. — 1963;89:37—42.26. McKiernan J., Simmons R., Katz J., Russo P. Natural history of chronic renal insufficiency after partial and radical nephrectomy // Urology. — 2002;59(6):816—820.McKiernan J., Simmons R., Katz J., Russo P. Natural history of chronic renal insufficiency after partial and radical nephrectomy // Urology. — 2002;59(6):816—820.27. Lau W.K., Blute M.L., Weaver A.L. et al. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney // Mayo Clin. Proc. — 2000;75(12):1236—1242.Lau W.K., Blute M.L., Weaver A.L. et al. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney // Mayo Clin. Proc. — 2000;75(12):1236—1242.28. Novick A.C. Laparoscopic and partial nephrectomy // Clin. Cancer. Res. — 2004; 15;10(18 Pt 2):6322S—6327S.Novick A.C. Laparoscopic and partial nephrectomy // Clin. Cancer. Res. — 2004; 15;10(18 Pt 2):6322S—6327S.29. Gill I.S., Matin S.F., Desai M.M. et al. Comparative analysis of laparoscopic versus open partial nephrectomy for renal tumors in 200 patients // J. Urol. — 2003;170(1):64—68.Gill I.S., Matin S.F., Desai M.M. et al. Comparative analysis of laparoscopic versus open partial nephrectomy for renal tumors in 200 patients // J. Urol. — 2003;170(1):64—68.30. Seifman B.D., Hollenbeck B.K., Wolf J.S. Jr. Laparoscopic nephron-sparing surgery for a renal mass: 1-year minimum follow-up // J. Endourol. — 2004;18(8):783—786.Seifman B.D., Hollenbeck B.K., Wolf J.S. Jr. Laparoscopic nephron-sparing surgery for a renal mass: 1-year minimum follow-up // J. Endourol. — 2004;18(8):783—786.31. Hwang J.J., Walther M.M. Update on minimally invasive approaches to kidney tumors // Curr. Urol. Rep. — 2004;5(1):13—18.Hwang J.J., Walther M.M. Update on minimally invasive approaches to kidney tumors // Curr. Urol. Rep. — 2004;5(1):13—18.32. Cestari A., Guazzoni G., dell'Acqua V. et al. Laparoscopic cryoablation of solid renal masses: intermediate term followup // J. Urol. — 2004;172(4 Pt 1):1267—1270.Cestari A., Guazzoni G., dell'Acqua V. et al. Laparoscopic cryoablation of solid renal masses: intermediate term followup // J. Urol. — 2004;172(4 Pt 1):1267—1270.33. Kirkali Z., Tuzel E., Mungan M.U. Recent advances in kidney cancer and metastatic disease // BJU Int. — 2001;88(8):818—824.Kirkali Z., Tuzel E., Mungan M.U. Recent advances in kidney cancer and metastatic disease // BJU Int. — 2001;88(8):818—824.34. Huland E., Heinzer H. Renal cell carcinoma — innovative medical treatments // Curr. Opin. Urol. — 2004;14(4):239—244.Huland E., Heinzer H. Renal cell carcinoma — innovative medical treatments // Curr. Opin. Urol. — 2004;14(4):239—244.35. Bukowski R.M. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma // Semin. Oncol. — 2000;27:204—212.Bukowski R.M. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma // Semin. Oncol. — 2000;27:204—212.36. McDermott D.F., Regan M.M., Clark J.I. et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma // J. Clin. Oncol. — 2005; 1;23(1):133—141McDermott D.F., Regan M.M., Clark J.I. et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma // J. Clin. Oncol. — 2005; 1;23(1):133—14137. Waters J.S., Moss C., Pyle L. et al. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma // Br. J. Cancer. — 2004; 15;91(10):1763—1768.Waters J.S., Moss C., Pyle L. et al. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma // Br. J. Cancer. — 2004; 15;91(10):1763—1768.38. Nanus D.M., Garino A., Milowsky M.I. et al. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma // Cancer. — 2004; 1;101(7):1545—1551.Nanus D.M., Garino A., Milowsky M.I. et al. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma // Cancer. — 2004; 1;101(7):1545—1551.39. Lipton A., Colombo-Berra A., Bukowski R.M. et al. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid // Clin. Cancer Res. — 2004; 15;10(18 Pt 2):6397—6403.Lipton A., Colombo-Berra A., Bukowski R.M. et al. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid // Clin. Cancer Res. — 2004; 15;10(18 Pt 2):6397—6403.40. Aass N., De Mulder P.H., Mickisch G.H. et al. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951) // J. Clin. Oncol. — 2005; 20;23(18):4172—4178.Aass N., De Mulder P.H., Mickisch G.H. et al. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951) // J. Clin. Oncol. — 2005; 20;23(18):4172—4178.41. Rackley R., Novick A., Klein E. et al. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma // J. Urol. — 1994;152:1399—1403.Rackley R., Novick A., Klein E. et al. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma // J. Urol. — 1994;152:1399—1403.42. Mickisch G.H., Garin A., Madej M., Sylvester R. Tumour nephrectomy plus interferon-a is superior to interferon-alone in metastatic renal cell carcinoma // J. Urol. — 2000; 163: 778A.Mickisch G.H., Garin A., Madej M., Sylvester R. Tumour nephrectomy plus interferon-a is superior to interferon-alone in metastatic renal cell carcinoma // J. Urol. — 2000; 163: 778A.43. Staehler G., Brkovic D. The role of radical surgery for renal cell carcinoma with extension into the vena cava // J. Urol. — 2000;163:1671—1675.Staehler G., Brkovic D. The role of radical surgery for renal cell carcinoma with extension into the vena cava // J. Urol. — 2000;163:1671—1675.44. Stadler W.M., Kuzel T., Shapiro C. et al. A multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal cell carcinoma // J. Clin. Oncol. — 1999;17:2541—2545.Stadler W.M., Kuzel T., Shapiro C. et al. A multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal cell carcinoma // J. Clin. Oncol. — 1999;17:2541—2545.45. De Mulder P.H., van Herpen C.M., Mulders P.A. Current treatment of renal cell carcinoma // Ann. Oncol. — 2004;15, Suppl. 4: 319—328.De Mulder P.H., van Herpen C.M., Mulders P.A. Current treatment of renal cell carcinoma // Ann. Oncol. — 2004;15, Suppl. 4: 319—328.46. Oosterwijk E., Divgi C.R., Brouwers A. et al. Monoclonal antibody-based therapy for renal cell carcinoma // Urol. Clin. North Am. — 2003;30(3):623—631.Oosterwijk E., Divgi C.R., Brouwers A. et al. Monoclonal antibody-based therapy for renal cell carcinoma // Urol. Clin. North Am. — 2003;30(3):623—631.